26 recruiting. 26 Phase 2, 8 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Recruiting 26 |
| Phase 1 | 8 | Recruiting 8 |
| Phase 3 | 4 | Recruiting 4 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders Glycerol Phenylbutyrate - SLC6A1 | Phase 2 | Recruiting | Scripps Translational Science Institute | 20 | 2026-10-01 | 2026-09-29 |
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy JZP926 capsule, Placebo - Juvenile Myoclonic Epilepsy | Phase 2 / Phase 3 | Recruiting | Jazz Pharmaceuticals | 260 | 2026-09-18 | 2026-10-06 |
| Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring Probenecid, Placebo - Focal Epilepsy | Phase 2 | Recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 600 | 2026-08-24 | 2026-10-05 |
| ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome ION337 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Ionis Pharmaceuticals, Inc. | 32 | 2026-05-21 | 2026-09-03 |
| A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures RAP-219 - Focal Epilepsy, Epilepsy | Phase 2 | Recruiting | Rapport Therapeutics Inc. | 30 | 2025-12-15 | 2026-01-23 |
| Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. Antisense oligonucleotide treatment (ASO) - GNAO1, Epilepsy | Phase 1 / Phase 2 | Recruiting | Pirogov Russian National Research Medical University | 5 | 2025-09-09 | 2026-01-23 |
| An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy CB03-154 - Focal Epilepsy | Phase 2 | Recruiting | Shanghai Zhimeng Biopharma, Inc. | 144 | 2025-08-14 | 2025-11-20 |
| A Study to Prevent Infantile Spasms Relapse Prednisolone, Famotidine, Placebo - Infantile Spasms, Infantile Epileptic Spasms Syndrome | Phase 2 | Recruiting | University of California, Los Angeles | 40 | 2025-05-05 | 2025-05-08 |
| Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy Ferumoxytol - Epilepsy, Temporal Lobe | Phase 2 | Recruiting | University of Alberta | 50 | 2025-05-01 | 2026-05-08 |
| RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures SPN-817, Placebo - Focal Onset Seizures | Phase 2 | Recruiting | Supernus Pharmaceuticals, Inc. | 216 | 2024-12-30 | 2026-10-01 |
| BMB-101 in Absence Epilepsy and DEE BMB-101 - Absence Epilepsy, Jeavons Syndrome | Phase 2 | Recruiting | Bright Minds Biosciences Pty Ltd | 20 | 2024-12-05 | 2025-08-12 |
| A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease ION283 - Lafora Disease | Phase 1 / Phase 2 | Recruiting | Berge Minassian | 10 | 2024-12-03 | 2025-12-18 |
| A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) NRTX-1001 - Epilepsy, Temporal Lobe | Phase 1 / Phase 2 | Recruiting | Neurona Therapeutics | 10 | 2024-11-14 | 2026-01-07 |
| A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy NaviFUS System - Drug Resistant Epilepsy, Epilepsy | Phase 1 / Phase 2 | Recruiting | NaviFUS Corporation | 8 | 2024-09-13 | 2026-09-15 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 20mg group - Focal Epilepsy | Phase 2 | Recruiting | Shanghai Zhimeng Biopharma, Inc. | 180 | 2024-08-14 | 2026-09-22 |
| AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy AAV9-hSyn1-miGRIK2 - Mesial Temporal Lobe Epilepsy | Phase 1 / Phase 2 | Recruiting | UniQure Biopharma B.V. | 12 | 2024-06-12 | 2026-08-24 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Encoded Therapeutics | 113 | 2024-05-14 | 2026-10-23 |
| Treatment of Refractory Infantile Spasms With Fenfluramine Fenfluramine - Infantile Spasm | Phase 2 | Recruiting | Children's Hospital of Orange County | 10 | 2023-06-16 | 2026-04-15 |
| Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy SPN-817 - Epilepsy, Seizures, Epileptic | Phase 2 | Recruiting | Supernus Pharmaceuticals, Inc. | 60 | 2023-02-07 | 2026-04-21 |
| Exogenous Ketone Esters for Drug Resistant Epilepsy Exogenous ketone ester - Drug Resistant Epilepsy | Phase 2 / Phase 3 | Recruiting | Sohag University | 60 | 2023-01-10 | 2024-11-27 |
Showing 20 of 26. Sign in to see all of them.
Epilepsies, Partial (6) · Epilepsies, Myoclonic (4) · Seizures (4) · Drug Resistant Epilepsy (2) · Epilepsy, Temporal Lobe (2) · Spasms, Infantile (2) · Delirium (1) · Epilepsy, Absence (1) · Epileptic Syndromes (1) · Generalized Epilepsy With Febrile Seizures Plus, Type 2 (1) · Glioblastoma (1) · Hippocampal Sclerosis (1) · Hyperkinesis (1) · Lafora Disease (1)
Brain Diseases (26) · Central Nervous System Diseases (26) · Nervous System Diseases (26) · Epileptic Syndromes (10) · Epilepsy, Generalized (8) · Pathological Conditions, Signs and Symptoms (7) · Neurologic Manifestations (6) · Signs and Symptoms (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (3) · Congenital Abnormalities (2) · Epilepsies, Myoclonic (2) · Epilepsies, Partial (2) · Heredodegenerative Disorders, Nervous System (2)
Amiloride (1) · Celecoxib (1) · Cenobamate (1) · Chlorpromazine (1) · Famotidine (1) · Fenfluramine (1) · Ferrosoferric Oxide (1) · Fluid Therapy (1) · Gabapentin (1) · Haloperidol (1) · Memantine (1) · Pentoxifylline (1) · Phenytoin (1) · Population Groups (1) · Prednisolone (1)
Shanghai Zhimeng Biopharma, Inc. (2) · Supernus Pharmaceuticals, Inc. (2) · Berge Minassian (1) · Bright Minds Biosciences Pty Ltd (1) · Centre Hospitalier Universitaire de Nice (1) · Children's Hospital of Orange County (1) · Encoded Therapeutics (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · Ionis Pharmaceuticals, Inc. (1) · Jazz Pharmaceuticals (1) · Katarzyna Kotulska (1) · M.D. Anderson Cancer Center (1) · Mostafa Bahaa (1) · NaviFUS Corporation (1) · Neurona Therapeutics (1)
United States (14) · Australia (6) · Canada (2) · Egypt (2) · France (2) · Poland (2) · Bulgaria (1) · Hungary (1) · Japan (1) · Russia (1) · Switzerland (1) · United Kingdom (1)
Maciej Gasior, MD, PhD (2) · Abdelrahim A Sadek, MD, PhD (1) · Berge Minassian, MD (1) · Daniel Shrey, MD (1) · David Hui, MD (1) · Donald Gross, MD (1) · Eduardo Dunayevich, MD (1) · Elena D Belousova, Prof (1) · Hans-Georg Wirsching, MD (1) · Imran Quraishi, MD (1) · Katarzyna Kotulska-Jozwiak (1) · Kristen Barbour, MD (1) · Project Leader (1)
PMID 16450381, PMID 16611468, PMID 40739381
K12TR004410 (1)